n Southern African Journal of HIV Medicine - Message from the Executive

Volume 14, Issue 3
  • ISSN : 1608-9693
  • E-ISSN: 2078-6751



Fellow HIV Clinicians, by now I am sure that most of you know that the World Health Organization (WHO) issued new guidelines. One of the most important differences is that these guidelines suggest initiating HIV-positive individuals on antiretroviral therapy (ART) at a CD4+ count of 500 cells/µl. This has caused much debate. With fixed-dose combination (FDC) treatment (one pill once daily) and medications with low side-effect profiles now available, many of the arguments for delayed therapy have fallen away. However, there is no clear clinical evidence of a benefit to starting ART earlier.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error